Sargent & Krahn
We are only able to display limited information for this firm. We display more complete information for all of the following firms:
The IP branch of law firm Cariola Díez Pérez-Cotapos, Sargent & Krahn fields a sizeable team that covers life sciences-related regulatory matters and litigation, as well as data protection and clinical trial contracts. With ‘deep technical knowledge and sophisticated legal strategies’, the group is also highly rated for its expertise in bioequivalency and biosimilarity, in relation to chemical and biotech pharmaceutical products, along with life sciences-related IP rights. Other notable areas include public bidding processes for pharmaceutical product acquisitions, as well as advertising and promotional issues. The department additionally assists innovation departments from Chilean universities with national and international patent prosecutions and pharmaceutical product contracts. Patent group head Juan Pablo Egaña assists with both patent applications before the administrative authorities and the enforcement of industrial property rights before Chile’s courts of justice; and Cristian Barros M specialises in IP law and pharmaceutical regulation. At associate level, Juan Francisco Peralta’s recent experience includes orphan drug-related mandates; Alejandra Varela‘s track record includes pharmaceutical patent appeals before the Industrial Property Court and healthcare sector regulatory matters; Macarena Correa’s experience includes advising on life sciences-related legislation; and Valentina Stark assists with the administrative law side to pharmaceutical regulatory issues.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Sargent & Krahn's main strengths in life sciences are its deep technical knowledge and sophisticated legal strategies.’
‘It is rare to find a team with a solid grasp of both the healthcare regulatory framework and the IP that is applied to the pharmaceutical and biotechnology industries.’
Key clients
- Cámara de la Innovación Farmacéutica
 - Universidad Católica de Chile
 
Work highlights
Assisted Regeneron Pharmaceuticals with the rejection of its patent application by the Chilean PTO, due to alleged lack of inventive step.


